Treatment strategy of pancreatic cancer by regulating FGFR2IIIc isoform

点击翻译按钮获取中文摘要

Fibroblast Growth Factor Receptor 2 IIIc (FGFR-2 IIIc) was abundant in 70% of pancreatic cancer cases, which correlated with the decreased duration of the development of liver metastasis after surgery. FGFR-2 IIIc transfected cells exhibited increased proliferation in vitro and formed larger subcutaneous and orthotopic tumors. Suppression of FGFR-2 IIIc expression inhibited the proliferation of pancreatic cancer cells, whereas an anti-FGFR-2 IIIc antibody inhibited the proliferation and migration of the cells (Ishiwata et al., Am J Pathol, 2012). Epithelial Splicing Regulatory Protein1 (ESRP1) binds the FGFR2 in the intron between exon IIIb and IIIc, and primarily promotes FGFR-2 IIIb expression. ESRP1 transfected pancreatic cancer cells formed significantly fewer liver metastases as compared to control cells. Thus, high FGFR-2 IIIc levels in pancreatic cancer contribute to disease aggressiveness, and FGFR-2 IIIc may be a noveland important therapeutic target in pancreatic cancer.